Drug Update · Hematology

AURORA: Bitopertin Reduced Protoporphyrin‑IX 49.8% in Erythropoietic Protoporphyria

July 22, 2026

Trial

AURORA

Primary result

-49.8% change in whole‑blood metal‑free protoporphyrin‑IX with bitopertin 60 mg versus placebo at day 121

Comparator

placebo

Orphan designation

Designated 12/22/2022; Not FDA Approved for Orphan Indication

Clinical Perspective

For adults with erythropoietic protoporphyria similar to the trial population (symptomatic adults with elevated whole‑blood metal‑free protoporphyrin‑IX), the AURORA data show dose‑dependent reductions in whole‑blood metal‑free protoporphyrin‑IX and improved measures of sunlight tolerance over 17 weeks ^[1]. Will these biomarker and sunlight‑tolerance effects translate into durable reductions in phototoxic reactions and sustained improvements in quality of life with longer follow‑up and in larger, more diverse populations?

Dr. Shruti Pandey · Hematology

The randomized, double-blind, placebo-controlled AURORA trial reported that once-daily oral bitopertin produced a percentage change from baseline in whole-blood metal-free protoporphyrin‑IX versus placebo of -29.6% with bitopertin 20 mg (consult current prescribing information for full dosing guidance) (P = .004) and -49.8% with bitopertin 60 mg (consult current prescribing information for full dosing guidance) (P < .001) at day 121 in adults with erythropoietic protoporphyria (EPP) ^[1]. The trial also reported a reduced incidence of phototoxic reactions and described bitopertin as well tolerated with no notable safety concerns identified ^[1].

Clinical Context

Erythropoietic protoporphyria is a rare genetic disorder of heme biosynthesis characterized by protoporphyrin‑IX accumulation, painful phototoxic reactions, and hepatobiliary disease, for which no disease‑modifying therapies are approved, according to the AURORA trial report ^[1]. Bitopertin is an inhibitor of glycine transporter 1 evaluated as an oral disease‑modifying candidate in adults with EPP ^[1]. The sponsor listed for bitopertin’s orphan designation is Disc Medicine; the FDA granted orphan designation for treatment of erythropoietic protoporphyria on 12/22/2022, and the FDA Orphan Approval Status listed in the public record is "Not FDA Approved for Orphan Indication" ^[2]. The AURORA trial was a phase 2 randomized, double‑blind evaluation of two doses versus placebo in symptomatic adults with EPP ^[1].

Key Findings

At day 121, the percentage change from baseline in whole‑blood metal‑free protoporphyrin‑IX versus placebo was -29.6% (P = .004) with bitopertin 20 mg (consult current prescribing information for full dosing guidance) and -49.8% (P < .001) with bitopertin 60 mg (consult current prescribing information for full dosing guidance) in the randomized, double‑blind, placebo‑controlled AURORA trial ^[1].
(consult current prescribing information for full dosing guidance)
Patients received bitopertin 20 mg (n = 26), bitopertin 60 mg (n = 25), or placebo (n = 24) once daily for 17 weeks in the trial ^[1].
Bitopertin was associated with a reduced incidence of phototoxic reactions and with improved measures of sunlight tolerance, as reported in the trial publication ^[1].
The investigators described bitopertin as well tolerated in the study population and reported no notable safety concerns identified in the provided trial excerpts ^[1].

Safety & Tolerability

Bitopertin was described as well tolerated with no notable safety concerns identified in the provided source excerpts ^[1].

Study Design

The AURORA trial was a randomized, double‑blind, phase 2 study in adults with erythropoietic protoporphyria in which patients received once‑daily oral bitopertin 20 mg (consult current prescribing information for full dosing guidance), bitopertin 60 mg (consult current prescribing information for full dosing guidance), or placebo for 17 weeks ^[1]. The primary endpoint was percentage change from baseline in whole‑blood metal‑free protoporphyrin‑IX levels at day 121 ^[1]. Patients were assigned to bitopertin 20 mg (n = 26), bitopertin 60 mg (n = 25), or placebo (n = 24) ^[1]. The publication notes limitations including small sample size, short follow‑up, and no formal adjustments for between‑group multiple pairwise comparisons ^[1]. The FDA OOPD listing shows an orphan designation for bitopertin on 12/22/2022 and lists the orphan approval status as Not FDA Approved for Orphan Indication; Disc Medicine is identified as the sponsor in that record ^[2].

FAQ

Q1 What did the AURORA trial show?

The AURORA trial showed that once‑daily oral bitopertin produced dose‑dependent reductions in whole‑blood metal‑free protoporphyrin‑IX versus placebo at day 121, with a percentage change versus placebo of -29.6% for bitopertin 20 mg (P = .004) and -49.8% for bitopertin 60 mg (P < .001). The trial also reported a reduced incidence of phototoxic reactions and described bitopertin as well tolerated in the study population. The trial enrolled adults with erythropoietic protoporphyria and treated participants for 17 weeks.

Q2 Who was enrolled in the AURORA trial?

Adults with erythropoietic protoporphyria were enrolled in the randomized, double‑blind, phase 2 AURORA study. Patients were randomized to once‑daily oral bitopertin 20 mg (n = 26), bitopertin 60 mg (n = 25), or placebo (n = 24) and followed for 17 weeks with the primary endpoint assessed at day 121. The publication lists the trial population and the randomized group sizes in the reported results.

Q3 What were the side effects reported in the AURORA trial?

Safety information provided in the AURORA trial excerpts indicates that bitopertin was well tolerated and that no notable safety concerns were identified in the published report. The trial report also stated that bitopertin was associated with a reduced incidence of phototoxic reactions. Specific adverse‑event frequencies and detailed safety tables were not included in the provided source excerpts.

Q4 What does the AURORA trial mean for clinical practice?

The AURORA data support that bitopertin can reduce whole‑blood metal‑free protoporphyrin‑IX and improve measures of sunlight tolerance over the 17‑week study period in adults with erythropoietic protoporphyria, suggesting it is a candidate disease‑modifying therapy warranting further study. The FDA record shows bitopertin had orphan designation for treatment of EPP on 12/22/2022 but is listed as Not FDA Approved for the orphan indication; the trial results alone do not indicate regulatory approval. Longer, larger studies with prespecified clinical endpoints and extended safety follow‑up are needed before changes in routine management can be recommended. (consult current prescribing information for full dosing guidance)

AURORA: Bitopertin Reduced Protoporphyrin‑IX 49.8% in Erythropoietic Protoporphyria

AURORA: Bitopertin Reduced Protoporphyrin‑IX 49.8% in Erythropoietic Protoporphyria

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Hematology in your inbox.

Related Clinical Updates

narsoplimab: FDA Approves for TA-TMA; 61% TMA Response

FDA Approves Daratumumab for NDMM Ineligible for ASCT: 52.3% MRD

FDA Approves Fitusiran for Hemophilia A/B: Median Treated ABR 3.7

Verified HCP Portal